Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute – Waldenström Macroglobulinemia 1
Kasyapa S. Chitta(Mayo Clinic in Florida), Asher Chanan‐Khan(WinnMed), Taimur Sher(Mayo Clinic in Florida), Richard R. Furman(Cornell University), Aneel Paulus(WinnMed), David Personett, Jeffrey M. Conroy(Roswell Park Comprehensive Cancer Center), Peter Martin(Northwestern University), Sheila N.J. Sait(Roswell Park Comprehensive Cancer Center), Sikander Ailawadhi(Jacksonville College), Aisha Masood(Novartis (United States)), Stephen M. Ansell(Mayo Clinic), Kelvin H. Lee(United Lincolnshire Hospitals NHS Trust), Petr Starostik(University of Florida), Morton Coleman(Cornell University), Norma J. Nowak(Roswell Park Comprehensive Cancer Center), Barbara A. Foster(Roswell Park Comprehensive Cancer Center), Kena C. Miller(Maryland Oncology Hematology), Michael T. Moser
Cited by 27
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
A gene expression atlas of the central nervous system based on bacterial artificial chromosomes
|Nature|2003|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k